(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 43 283.00 |
Vidutinė apimtis | 109 106 |
Rinkos kapitalizacija | 27.80B |
EPS | $0.598 ( 2023-06-30 ) |
Kita pelno data | ( $0.0800 ) 2024-05-09 |
Last Dividend | $0.0740 ( 2023-05-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | 38.78 |
ATR14 | $0.0210 (0.17%) |
Tūris Koreliacija
Coloplast A/S Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Coloplast A/S Koreliacija - Valiuta/Žaliavos
Coloplast A/S Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $24.50B |
Bruto pelnas: | $16.33B (66.64 %) |
EPS: | $22.21 |
FY | 2023 |
Pajamos: | $24.50B |
Bruto pelnas: | $16.33B (66.64 %) |
EPS: | $22.21 |
FY | 2022 |
Pajamos: | $22.58B |
Bruto pelnas: | $15.53B (68.78 %) |
EPS: | $22.15 |
FY | 2021 |
Pajamos: | $19.43B |
Bruto pelnas: | $13.31B (68.53 %) |
EPS: | $2.27 |
Financial Reports:
No articles found.
Coloplast A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.210 (N/A) |
$0 (N/A) |
$0.0740 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0810 | 2021-05-14 |
Last Dividend | $0.0740 | 2023-05-19 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $0.649 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.9 | -- |
Div. Sustainability Score | 6.57 | |
Div.Growth Potential Score | 5.74 | |
Div. Directional Score | 6.15 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PCLB | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
DIMC | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
UEPCO | Ex Dividend Knight | 2023-07-20 | Quarterly | 0 | 0.00% | |
JMPLY | Ex Dividend Knight | 2023-06-15 | Semi-Annually | 0 | 0.00% | |
BKHYY | Ex Dividend Junior | 2023-08-25 | Annually | 0 | 0.00% | |
RMYHY | Ex Dividend Junior | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
EVSBY | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
WJRYF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
LNSTY | Ex Dividend Knight | 2023-08-17 | Semi-Annually | 0 | 0.00% | |
CGEMY | Ex Dividend Knight | 2023-05-25 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.195 | 1.500 | 6.11 | 9.16 | [0 - 0.5] |
returnOnAssetsTTM | 0.100 | 1.200 | 6.66 | 7.99 | [0 - 0.3] |
returnOnEquityTTM | 0.424 | 1.500 | 6.40 | 9.60 | [0.1 - 1] |
payoutRatioTTM | 0.957 | -1.000 | 0.433 | -0.433 | [0 - 1] |
currentRatioTTM | 0.532 | 0.800 | -2.34 | -1.871 | [1 - 3] |
quickRatioTTM | 0.324 | 0.800 | -2.80 | -2.24 | [0.8 - 2.5] |
cashRatioTTM | 0.0484 | 1.500 | -0.842 | -1.263 | [0.2 - 2] |
debtRatioTTM | 0.445 | -1.500 | 2.58 | -3.87 | [0 - 0.6] |
interestCoverageTTM | 9.31 | 1.000 | 7.66 | 7.66 | [3 - 30] |
operatingCashFlowPerShareTTM | 25.30 | 2.00 | 1.568 | 3.14 | [0 - 30] |
freeCashFlowPerShareTTM | 19.61 | 2.00 | 0.195 | 0.389 | [0 - 20] |
debtEquityRatioTTM | 1.430 | -1.500 | 4.28 | -6.42 | [0 - 2.5] |
grossProfitMarginTTM | 0.667 | 1.000 | 2.21 | 2.21 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.273 | 1.000 | 6.53 | 6.53 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.256 | 1.000 | 9.69 | 9.69 | [0.2 - 2] |
assetTurnoverTTM | 0.515 | 0.800 | 9.90 | 7.92 | [0.5 - 2] |
Total Score | 6.57 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.86 | 1.000 | 9.71 | 0 | [1 - 100] |
returnOnEquityTTM | 0.424 | 2.50 | 7.69 | 9.60 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.61 | 2.00 | 3.46 | 0.389 | [0 - 30] |
dividendYielPercentageTTM | 0.0516 | 1.500 | 8.71 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 25.30 | 2.00 | 1.568 | 3.14 | [0 - 30] |
payoutRatioTTM | 0.957 | 1.500 | 0.433 | -0.433 | [0 - 1] |
pegRatioTTM | 2.06 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.221 | 1.000 | 6.97 | 0 | [0.1 - 0.5] |
Total Score | 5.74 |
Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.